[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, CA: a cancer journal for clinicians 69(1) (2019) 7-34.
[2] S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, H. Friess, J. Kleeff, Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages, PLoS Med 7(4) (2010) e1000267.
[3] M.I. Canto, F. Harinck, R.H. Hruban, G.J. Offerhaus, J.W. Poley, I. Kamel, et al., International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer, Gut 62(3) (2013) 339-47.
[4] M. Del Chiaro, C.S. Verbeke, N. Kartalis, R. Pozzi Mucelli, P. Gustafsson, J. Hansson, et al., Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer, JAMA surgery 150(6) (2015) 512-8.
[5] R. Pannala, J.B. Leirness, W.R. Bamlet, A. Basu, G.M. Petersen, S.T. Chari, Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus, Gastroenterology 134(4) (2008) 981-7.
[6] A. Sharma, T.C. Smyrk, M.J. Levy, M.A. Topazian, S.T. Chari, Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis, Gastroenterology 155(2) (2018) 490-500 e2.
[7] G. Aggarwal, V. Ramachandran, N. Javeed, T. Arumugam, S. Dutta, G.G. Klee, et al., Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice, Gastroenterology 143(6) (2012) 1510-1517 e1.
[8] M. Pelaez-Luna, N. Takahashi, J.G. Fletcher, S.T. Chari, Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis, The American journal of gastroenterology 102(10) (2007) 2157-63.
[9] R. Pannala, A. Basu, G.M. Petersen, S.T. Chari, New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer, The Lancet. Oncology 10(1) (2009) 88-95.
[10] W.H.O.I.D. Federation., Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia : report of a WHO/IDF consultation / World Health Organization, International Diabetes Federation., Geneva, Switzerland : World Health Organization2006.
[11] S.T. Chari, C.L. Leibson, K.G. Rabe, L.J. Timmons, J. Ransom, M. de Andrade, et al., Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer, Gastroenterology 134(1) (2008) 95-101.
[12] P. Maisonneuve, A.B. Lowenfels, Risk factors for pancreatic cancer: a summary review of meta-analytical studies, Int J Epidemiol 44(1) (2015) 186-98.
[13] R. Carreras-Torres, M. Johansson, V. Gaborieau, P.C. Haycock, K.H. Wade, C.L. Relton, et al., The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study, Journal of the National Cancer Institute 109(9) (2017).
[14] C.K. Chu, A.E. Mazo, M. Goodman, V. Egnatashvili, J.M. Sarmiento, C.A. Staley, et al., Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma, Annals of surgical oncology 17(2) (2010) 502-13.
[15] P.A. Hart, S.T. Chari, Diabetes mellitus and pancreatic cancer: why the association matters?, Pancreas 42(8) (2013) 1207-9.
[16] J. Kleeff, E. Costello, R. Jackson, C. Halloran, W. Greenhalf, P. Ghaneh, et al., The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer, British journal of cancer 115(7) (2016) 887-94.
[17] M. Del Chiaro, C. Verbeke, R. Salvia, G. Kloppel, J. Werner, C. McKay, et al., European experts consensus statement on cystic tumours of the pancreas, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 45(9) (2013) 703-11.
[18] D. Li, Diabetes and pancreatic cancer, Mol Carcinog 51(1) (2012) 64-74.
[19] J. Permert, J. Larsson, G.T. Westermark, M.K. Herrington, L. Christmanson, P.M. Pour, et al., Islet amyloid polypeptide in patients with pancreatic cancer and diabetes, The New England journal of medicine 330(5) (1994) 313-8.
[20] L. Wang, B. Zhang, W. Zheng, M. Kang, Q. Chen, W. Qin, et al., Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway, Sci Rep 7(1) (2017) 5384.
[21] M. Norberg, S. Wall, K. Boman, L. Weinehall, The Vasterbotten Intervention Programme: background, design and implications, Global health action 3 (2010).